Theranostic Advances in Breast Cancer in Nuclear Medicine

被引：52

作者：

Vahidfar, Nasim ^{[1
]}

Aghanejad, Ayuob ^{[2
]}

Ahmadzadehfar, Hojjat ^{[3
]}

Farzanehfar, Saeed ^{[1
]}

Eppard, Elisabeth ^{[4
,5
]}

机构：

[1] Univ Tehran Med Sci, Vali Asr Hosp, Dept Nucl Med, Tehran 1419733141, Iran

[2] Tabriz Univ Med Sci, Biomed Inst, Res Ctr Pharmaceut Nanotechnol, Tabriz 51368, Iran

[3] Klinikum Westfalen, Dept Nucl Med, D-44149 Dortmund, Germany

[4] Positronpharma SA, Rancagua 878, Santiago 7500621, Chile

[5] Univ Hosp Magdeburg, Dept Nucl Med, Leipziger Str 44, D-39120 Magdedurg, Germany

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 09期

关键词：

theranostic; radiopharmaceutical; imaging; therapy; GASTRIN-RELEASING-PEPTIDE; NEUROENDOCRINE TUMORS; BOMBESIN RECEPTORS; PET; EXPRESSION; DIAGNOSIS; SUBTYPES; FIBROBLASTS; LIGANDS; PATIENT;

D O I：

10.3390/ijms22094597

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The implication of 'theranostic' refers to targeting an identical receptor for diagnostic and therapeutic purposes, by the same radioligand, simultaneously or separately. In regard to extensive efforts, many considerable theranostic tracers have been developed in recent years. Emerging evidence strongly demonstrates the tendency of nuclear medicine towards therapies based on a diagnosis. This review is focused on the examples of targeted radiopharmaceuticals for the imaging and therapy of breast cancer.

引用

页数：17

共 50 条

[1] Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine
Hu, Mei
Zhang, Chenshuo
Fan, Dandan
Yang, Ru
Bai, Yongxiang
Shi, Haibin
ACS APPLIED MATERIALS & INTERFACES, 2025, 17 (03) : 4337 - 4353
[2] Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
Montemagno, Christopher
Pages, Gilles
CANCERS, 2020, 12 (04)
[3] Theranostic and nanotheranostic probes in nuclear medicine
Drude, Natascha
Tienken, Lena
Mottaghy, Felix M.
METHODS, 2017, 130 : 14 - 22
[4] Nuclear medicine tools for the development of personalized medicine in breast cancer
Rousseau, C.
Lacombe, M.
Pallardy, A.
Eugene, T.
Bodet-Milin, C.
Ansquer, C.
Rusu, D.
Kraeber-Bodere, F.
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2012, 36 (04): : 233 - 236
[5] Advances in polymer-centric nanomedicines for theranostic cancer treatment
Bag, Anindita
Maheshwari, Rahul
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 100
[6] Nuclear Medicine and Cancer Theragnostics: Basic Concepts
Zoi, Vasiliki
Giannakopoulou, Maria
Alexiou, George A.
Bouziotis, Penelope
Thalasselis, Savvas
Tzakos, Andreas G.
Fotopoulos, Andreas
Papadopoulos, Athanassios N.
Kyritsis, Athanassios P.
Sioka, Chrissa
DIAGNOSTICS, 2023, 13 (19)
[7] Genomic basis for breast cancer: advances in personalized medicine
Hidalgo-Miranda, Alfredo
Jimenez-Sanchez, Gerardo
SALUD PUBLICA DE MEXICO, 2009, 51 : S197 - S207
[8] Theranostic application of miR-429 in HER2+breast cancer
Cava, Claudia
Novello, Chiara
Martelli, Cristina
Lodico, Alessia
Ottobrini, Luisa
Piccotti, Francesca
Truffi, Marta
Corsi, Fabio
Bertoli, Gloria
Castiglioni, Isabella
THERANOSTICS, 2020, 10 (01): : 50 - 61
[9] Exosomal microRNAs in breast cancer: towards theranostic applications
Gulati, Richa
Mitra, Tridip
Rajiv, Rohan
Rajan, Emilda Judith Ezhil
Pierret, Chris
Enninga, Elizabeth Ann L.
Janardhanan, Rajiv
FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
[10] Nuclear medicine for imaging of epithelial ovarian cancer
Abedi, Seyed Mohammad
Mardanshahi, Alireza
Shahhosseini, Roza
Hosseinimehr, Seyed Jalal
FUTURE ONCOLOGY, 2016, 12 (09) : 1165 - 1177

← 1 2 3 4 5 →